Brief: Venus Concept Submits FDA 510(K) Related To The Use Of Its Aime Next Generation Robotic Technology For Tissue Excision And Skin Resurfacing
31/03/2022 22:09
March 31 (Reuters) - Venus Concept Inc VERO.O :
* VENUS CONCEPT SUBMITS FDA 510(K) RELATED TO THE USE OF ITS
AIME™
NEXT GENERATION ROBOTIC TECHNOLOGY FOR TISSUE EXCISION AND SKIN
RESURFACING
* VENUS CONCEPT INC - LOOK FORWARD TO BEGINNING A LIMITED
RELEASE
IN Q4 OF 2022
Source text for Eikon: ID:nGNX1fwbH2
Further company coverage: VERO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Venus Concept
See all newsNASDAQ RESUMED AT 09:00 AM
Brief: Venus Concept Announces Intention To Voluntary Delist From Nasdaq And Deregister With SEC
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Venus Concept Inc - On Dec 31, Co & Its Unit Enter Consent Agreement With Madryn Health Partners & Others - SEC Filing
Medical aesthetic device maker Venus Concept's Q3 revenue misses